Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

Share Price Information for IQ-AI (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.20
Bid: 1.10
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.20 (18.182%)
Open: 1.20
High: 1.20
Low: 1.20
Prev. Close: 1.20
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMAGING BIOMETRICS ANNOUNCES PARTNERSHIP

11 Apr 2018 07:00

RNS Number : 4904K
Flying Brands Limited
11 April 2018
 

 

 

FLYING BRANDS' SUBSIDIARY IMAGING BIOMETRICS ANNOUNCES DISTRIBUTION PARTNERSHIP WITH AI EXCHANGE PLATFORM, ENVOY AI

 

IB Neuro and IB Delta T1 Maps are now available on EnvoyAI's artificial intelligence Exchange

 

 

Flying Brand's newly acquired subsidiary Imaging Biometrics®, LLC ("IB"), a medical imaging software company specialising in advanced visualisation and analytics, has entered into a distribution agreement with EnvoyAI, a leading artificial intelligence ("AI") Exchange platform. IB Neuro, the premier magnetic resonance ("MR") imaging dynamic susceptibility contrast (DSC) perfusion solution, and IB's Delta T1 mapping algorithm, are now available for purchase on the EnvoyAI Exchange.

 

Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI said, "We recently added Imaging Biometrics' FDA cleared post-processing solutions to the EnvoyAI Exchange. The proprietary quantitative and automated algorithms contained in IB Neuro and IB Delta Suite provide clinicians with incredible value by producing unique imaging biomarkers that enable them to accurately monitor treatment response in brain tumor patients."

 

"This partnership with EnvoyAI enables immediate and widespread access to our proven and quantitative imaging biomarkers for neuro radiologists, neuro-oncologist, and neuro surgeons," said Michael Schmainda, CEO of IB. "The need to accurately quantify changes in brain tumor patients is becoming more important and yet increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents. The exclusive technology contained in IB's products overcome these difficulties and, through the unique additional information made available, aid the treatment team's ability to rapidly and objectively assess whether patients are responding to treatment. We are delighted to participate on the EnvoyAI Exchange and look forward to providing sophisticated imaging solutions to benefit clinicians and their patients."

 

About EnvoyAI (www.envoyai.com)

EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialisation processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Imaging Biometrics® LLCImaging Biometrics develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

About Flying Brands PLC

Flying Brands PLC (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGMDVGGGRZM
Date   Source Headline
6th Apr 200610:26 amRNSDirector/PDMR Shareholding
24th Mar 20064:17 pmRNSAdditional Listing - Replace
23rd Mar 20063:28 pmRNSAdditional Listing
16th Mar 20063:18 pmRNSDirector/PDMR Shareholding
14th Mar 20063:43 pmRNSAnnual Information Update
14th Mar 200612:26 pmRNSDirector/PDMR Shareholding
10th Mar 20067:01 amRNSDirectorate Change
10th Mar 20067:01 amRNSFinal Results
27th Feb 200611:00 amRNSNotice of Results
10th Jan 20067:00 amRNSTrading Statement
9th Dec 20054:07 pmRNSTransaction in Own Shares
14th Nov 20057:01 amRNSChange of Adviser
21st Oct 200512:28 pmRNSHolding(s) in Company
18th Oct 20058:00 amRNSTransaction in Own Shares
17th Oct 20057:00 amRNSTransaction in Own Shares
10th Oct 20054:39 pmRNSTransaction in Own Shares
30th Sep 200511:58 amRNSAcquisition of GBS-replacemt
30th Sep 20057:01 amRNSAcquisition of GBS
29th Sep 20054:00 pmRNSDirectorate Change
24th Aug 200512:18 pmRNSAdditional Listing
12th Aug 200512:58 pmRNSDirector/PDMR Shareholding
11th Aug 200511:58 amRNSAdditional Listing
11th Aug 200511:37 amRNSDirector Shareholding
9th Aug 200511:00 amRNSDirector Shareholding
29th Jul 20057:00 amRNSInterim Results
7th Jul 20057:00 amRNSNotice of Results
5th Jul 200511:00 amRNSChange of Adviser
12th May 20058:27 amRNSTransaction in Own Shares
20th Apr 20057:46 amRNSDirector Shareholding
18th Apr 20052:54 pmRNSAcquisition Completion
18th Apr 20059:32 amRNSDirector Shareholding
4th Apr 200512:00 pmRNSDirectorate Change
4th Apr 200512:00 pmRNSTrading Statement
24th Mar 20052:00 pmRNSDirectorate Change
11th Mar 20057:01 amRNS2004 Final Results
28th Feb 200512:55 pmRNSHolding(s) in Company
28th Jan 20059:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.